Literature DB >> 6411939

Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa.

G R Prout, W W Koontz, L J Coombs, I R Hawkins, G H Friedell.   

Abstract

We assigned randomly 90 patients treated previously for superficial transitional cell carcinoma to conventional followup or prophylactic treatment. This followup study details the late incidence of recurrence (29 of 45 patients in the prophylactic group and 34 of 45 controls), the progression of tumor grade and stage, the deaths and causes (24 patients), and the influence of initial stage, grade, carcinoma in situ and positive cytology on the outcome of treatment.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6411939     DOI： 10.1016/s0022-5347(17)51400-7

Source DB:  PubMed          Journal:  J Urol        ISSN： 0022-5347            Impact factor:   7.450


  11 in total

1.  Clinical studies on bladder tumor-associated antigen in serum of patients with bladder cancer by using monoclonal antibody and sandwich ELISA.

Authors:  S S Zhu; Y C Zhang; R Z Hu; Z Q Ye; C J Li; Q A Lin
Journal:  J Tongji Med Univ       Date:  1990

Review 2.  Intravesical drug delivery. Pharmacokinetic and clinical considerations.

Authors:  M S Highley; A T van Oosterom; R A Maes; E A De Bruijn
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 3.  Carcinoma in situ and treatment options.

Authors:  M Erton; Y Ilker
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

Review 4.  The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside.

Authors:  Jonathan J Duplisea; Sharada Mokkapati; Devin Plote; Kimberly S Schluns; David J McConkey; Seppo Yla-Herttuala; Nigel R Parker; Colin P Dinney
Journal:  World J Urol       Date:  2018-11-11       Impact factor: 4.226

Review 5.  Superficial bladder cancer: state of the art.

Authors:  A V Bono
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  Sequential instillation therapy with mitomycin C and adriamycin for superficial bladder tumors.

Authors:  I Fukui; H Sekine; K Kihara; T Yamada; T Kawai; M Washizuka; D Ishiwata; K Oka; K Hosoda; S Ikegami
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  Intravesical administration of pirarubicin against superficial bladder cancer: Relationship between tumor tissue concentration and exposure time in the bladder or therapeutic effect.

Authors:  Maki Arakawa; Kogenta Nakamura; Yoshiaki Yamada; Kimihito Kato; Remi Katsuda; Motoi Tobiume; Kenji Zennami; Masayuki Watanabe; Yoshiharu Kato; Genya Nishikawa; Takahiko Yoshizawa; Shigeyuki Aoki; Tomohiro Taki; Kenji Mitsui; Nobuaki Honda; Hiroko Saito; Takaaki Hasegawa
Journal:  Exp Ther Med       Date:  2011-06-30       Impact factor: 2.447

8.  A randomized trial of early intravesical instillation of epirubicin in superficial bladder cancer. The Nagoya University Urological Oncology Group.

Authors:  K Okamura; T Murase; K Obata; S Ohshima; Y Ono; T Sakata; Y Hasegawa; T Shimoji; K Miyake
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

9.  Karyometry in recurrent superficial transitional cell tumors of the bladder.

Authors:  H G van der Poel; R D van Caubergh; M E Boon; F M Debruyne; J A Schalken
Journal:  Urol Res       Date:  1992

10.  Current status of intravesical chemotherapy trials in the EORTC Urological Group. An overview.

Authors:  L Denis; C Bouffioux; K H Kurth; F Debruyne; R Sylvester; M De Pauw
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.